TABLE 1.
Demographics, clinical characteristics and depression screeninga results of 104 patients with ocular inflammatory disease.
| Overall (N=104) | Depressed (N=28) | Not Depressed (N=76) | P-value | |
|---|---|---|---|---|
| Demographics | ||||
| Female | 57 (54.8%) | 16 (57.1%) | 41 (53.9%) | .83b |
| Race | .01b | |||
| Caucasian | 51 (49.0%) | 12 (42.9%) | 39 (51.3%) | |
| Hispanic | 11 (10.6%) | 8 (28.6%) | 3 (3.9%) | |
| Asian | 23 (22.1%) | 3 (10.7%) | 20 (26.3%) | |
| Black | 10 (9.6%) | 2 (7.1%) | 8 (10.5%) | |
| Indian Subcontinent | 6 (5.8%) | 1 (3.6%) | 5 (6.6%) | |
| Native American | 2 (1.9%) | 1 (3.6%) | 1 (1.3%) | |
| Other | 1 (1.0%) | 1 (3.6%) | 0 (0.0%) | |
| Current smoker | 9 (8.7%) | 2 (7.1%) | 7 (9.2%) | .95b |
| Median household income in dollars (IQRd) | 94293 (77255, 121348) | 80268 (73158, 105766) | 95919 (81114, 125831) | .06c |
| Median age in years (IQRd) | 41.0 (32.0, 51.3) | 41.5 (30.8, 51.3) | 40.5 (32.8, 50.5) | .79c |
| Mean logMAR vision in the better eye (range) | 0.07 (−0.14, 0.6) | 0.12 (0, 0.54) | 0.05 (−0.14, 0.6) | .02c |
| Any systemic inflammatory disease | 42 (40.4%) | 13 (46.4%) | 29 (38.2%) | .50b |
| Ankylosing spondylitis | 12 (11.5%) | 1 (3.6%) | 11 (14.5%) | |
| Behcet’s disease | 1 (1.0%) | 0 (0%) | 1 (1.3%) | |
| Inflammatory bowel disease | 2 (1.9%) | 1 (3.6%) | 1 (1.3%) | |
| Juvenile idiopathic arthritis | 1 (1.0%) | 1 (3.6%) | 0 (0%) | |
| Mucous membrane pemphigoid (MMP) | 3 (2.9%) | 2 (7.1%) | 1 (1.3%) | |
| Multiple sclerosis | 1 (1.0%) | 1 (3.6%) | 0 (0%) | |
| Parry Romberg syndrome | 1 (1.0%) | 0 (0%) | 1 (1.3%) | |
| Reactive arthritis | 2 (1.9%) | 1 (3.6%) | 1 (1.3%) | |
| Rheumatoid arthritis | 2 (1.9%) | 1 (3.6%) | 1 (1.3%) | |
| Rosacea | 1 (1.0%) | 0 (0%) | 1 (1.3%) | |
| Sarcoidosis | 7 (6.7%) | 1 (3.6%) | 6 (7.9%) | |
| Systemic lupus erythematosus | 2 (1.9%) | 0 (0%) | 2 (2.6%) | |
| Tubulointerstitial nephritis and uveitis | 1 (1.0%) | 0 (0%) | 1 (1.3%) | |
| Vogt-Koyanagi-Harada syndrome | 6 (5.8%) | 4 (14.3%) | 2 (2.6%) | |
|
| ||||
| Clinical Course | ||||
| Median duration of disease in years (IQRd) | 5.8 (2.0, 12.0) | 3.9 (1.6, 9.3) | 6.3 (3.0, 12.3) | .18c |
| Chronic | 68 (65.4%) | 24 (85.7%) | 44 (57.9%) | .01b |
| Bilateral | 77 (74.0%) | 25 (89.3%) | 52 (68.4%) | .04b |
| Location of Inflammation | .01b | |||
| Anterior | 49 (47.1%) | 8 (28.6%) | 41 (53.9%) | |
| Intermediate | 8 (7.7%) | 0 (0%) | 8 (10.5%) | |
| Anterior + intermediate | 11 (10.6%) | 6 (21.4%) | 5 (6.6%) | |
| Posterior/Pan | 27 (25.9%) | 11 (39.2%) | 16 (21.1%) | |
| Scleritis | 4 (3.8%) | 1 (3.5%) | 3 (3.9%) | |
| Conjunctiva (MMP) | 3 (2.9%) | 2 (7.1%) | 1 (1.3%) | |
| Cornea (peripheral ulcerative keratitis) | 1 (1.0%) | 0 (0%) | 1 (1.3%) | |
| Orbit | 1 (1.0%) | 0 (0%) | 1 (1.3%) | |
| Current active inflammation | 26 (25.0%) | 7 (25.0%) | 19 (25.0%) | .99b |
|
| ||||
| Current Treatment | ||||
| Oral corticosteroid | 31 (29.8%) | 15 (53.5%) | 16 (21.1%) | .003b |
| Topical corticosteroid | 51 (49.0%) | 13 (46.4%) | 38 (50.0%) | .92b |
| Antimetabolite | 25 (24.0%) | 12 (42.9%) | 13 (17.1%) | .01b |
| Methotrexate | 13 (12.5%) | 6 (21.4%) | 7 (9.2%) | |
| Mycophenolate mofetil | 11 (10.6%) | 6 (21.4%) | 5 (6.6%) | |
| Azathioprine | 1 (1.0%) | 0 (0%) | 1 (1.3%) | |
| Cyclosporine | 1 (1.0%) | 1 (3.6%) | 0 (0%) | .27b |
| Cyclophosphamide | 2 (1.9%) | 2 (7.1%) | 0 (0%) | .07b |
| Biologic | 10 (9.6%) | 3 (10.7%) | 7 (9.2%) | .99b |
| Infliximab | 6 (5.8%) | 1 (3.6%) | 5 (6.6%) | |
| Adalimumab | 4 (3.8%) | 2 (7.1%) | 2 (2.6%) | |
| History of changing immunomodulatory therapy | 15 (14.4%) | 9 (32.1%) | 6 (7.9%) | .004b |
a
Beck Depression Inventory II: patients in the depressed group scored >13 and patients in the not depressed group scored ≤13
b
Analyzed using a Fisher Exact Test at a confidence level of 95%
c
Analyzed using a two-sided t-test at a confidence level of 95%
d
Interquartile range